APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chimeric Antigen Receptor (CAR) T-Cell Therapy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Outlook and Growth Opportunities 2026

21 December 2025196 pages

Choose your research edition.

Industry ResearchChimeric Antigen Receptor (CAR) T-Cell Therapy Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Chimeric Antigen Receptor (CAR) T-Cell Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Chimeric Antigen Receptor (CAR) T-Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Chimeric Antigen Receptor (CAR) T-Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chimeric Antigen Receptor (CAR) T-Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Chimeric Antigen Receptor (CAR) T-Cell Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Chimeric Antigen Receptor (CAR) T-Cell Therapy market include Allogene Therapeutics, Autolus Therapeutics, Bluebird Bio, CARsgen Therapeutics, Cellectis, Celyad, FOSUNKite, JW Therapeutics and Mustang Bio, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Chimeric Antigen Receptor (CAR) T-Cell Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Chimeric Antigen Receptor (CAR) T-Cell Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market.

Chimeric Antigen Receptor (CAR) T-Cell Therapy Segment by Company

Allogene Therapeutics

Autolus Therapeutics

Bluebird Bio

CARsgen Therapeutics

Cellectis

Celyad

FOSUNKite

JW Therapeutics

Mustang Bio

Sorrento Therapeutics

Bristol-Myers Squibb

Gilead Sciences

Novartis

J & J

Chimeric Antigen Receptor (CAR) T-Cell Therapy Segment by Type

CD19-targeted

BCMA-targeted

Chimeric Antigen Receptor (CAR) T-Cell Therapy Segment by Application

Lymphoma

Multiple Myeloma

Chimeric Antigen Receptor (CAR) T-Cell Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Chimeric Antigen Receptor (CAR) T-Cell Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Chimeric Antigen Receptor (CAR) T-Cell Therapy key companies, revenue, market share, and recent developments.

3. To split the Chimeric Antigen Receptor (CAR) T-Cell Therapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Chimeric Antigen Receptor (CAR) T-Cell Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Chimeric Antigen Receptor (CAR) T-Cell Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze Chimeric Antigen Receptor (CAR) T-Cell Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chimeric Antigen Receptor (CAR) T-Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chimeric Antigen Receptor (CAR) T-Cell Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Chimeric Antigen Receptor (CAR) T-Cell Therapy industry.

Chapter 3: Detailed analysis of Chimeric Antigen Receptor (CAR) T-Cell Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Chimeric Antigen Receptor (CAR) T-Cell Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Chimeric Antigen Receptor (CAR) T-Cell Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Trends Table 2. Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Drivers Table 3. Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Opportunities and Challenges Table 4. Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Restraints Table 5. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Share by Company (2021-2026) Table 7. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Key Company Manufacturing Base & Headquarters Table 9. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Company, Product Type & Application Table 10. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of CD19-targeted Table 15. Significant Companies of BCMA-targeted Table 16. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type (2021-2026) Table 20. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Lymphoma Table 22. Significant Companies of Multiple Myeloma Table 23. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application (2021-2026) Table 27. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application (2027-2032) Table 28. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Region (2021-2026) Table 31. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Region (2027-2032) Table 33. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Market Share by Country (2021-2026) Table 36. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Market Share by Country (2027-2032) Table 38. Allogene Therapeutics Company Information Table 39. Allogene Therapeutics Business Overview Table 40. Allogene Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Allogene Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 42. Allogene Therapeutics Recent Development Table 43. Autolus Therapeutics Company Information Table 44. Autolus Therapeutics Business Overview Table 45. Autolus Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Autolus Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 47. Autolus Therapeutics Recent Development Table 48. Bluebird Bio Company Information Table 49. Bluebird Bio Business Overview Table 50. Bluebird Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Bluebird Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 52. Bluebird Bio Recent Development Table 53. CARsgen Therapeutics Company Information Table 54. CARsgen Therapeutics Business Overview Table 55. CARsgen Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. CARsgen Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 57. CARsgen Therapeutics Recent Development Table 58. Cellectis Company Information Table 59. Cellectis Business Overview Table 60. Cellectis Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Cellectis Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 62. Cellectis Recent Development Table 63. Celyad Company Information Table 64. Celyad Business Overview Table 65. Celyad Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Celyad Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 67. Celyad Recent Development Table 68. FOSUNKite Company Information Table 69. FOSUNKite Business Overview Table 70. FOSUNKite Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. FOSUNKite Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 72. FOSUNKite Recent Development Table 73. JW Therapeutics Company Information Table 74. JW Therapeutics Business Overview Table 75. JW Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. JW Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 77. JW Therapeutics Recent Development Table 78. Mustang Bio Company Information Table 79. Mustang Bio Business Overview Table 80. Mustang Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Mustang Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 82. Mustang Bio Recent Development Table 83. Sorrento Therapeutics Company Information Table 84. Sorrento Therapeutics Business Overview Table 85. Sorrento Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Sorrento Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 87. Sorrento Therapeutics Recent Development Table 88. Bristol-Myers Squibb Company Information Table 89. Bristol-Myers Squibb Business Overview Table 90. Bristol-Myers Squibb Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Bristol-Myers Squibb Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 92. Bristol-Myers Squibb Recent Development Table 93. Gilead Sciences Company Information Table 94. Gilead Sciences Business Overview Table 95. Gilead Sciences Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Gilead Sciences Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 97. Gilead Sciences Recent Development Table 98. Novartis Company Information Table 99. Novartis Business Overview Table 100. Novartis Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Novartis Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 102. Novartis Recent Development Table 103. J & J Company Information Table 104. J & J Business Overview Table 105. J & J Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. J & J Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 107. J & J Recent Development Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Image Figure 2. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. CD19-targeted Image Figure 8. BCMA-targeted Image Figure 9. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type (2021-2032) Figure 12. Lymphoma Image Figure 13. Multiple Myeloma Image Figure 14. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application (2021-2032) Figure 17. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 20. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 26. South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • CD19-targeted
  • BCMA-targeted
Applications
  • Lymphoma
  • Multiple Myeloma
Companies covered
  • Allogene Therapeutics
  • Autolus Therapeutics
  • Bluebird Bio
  • CARsgen Therapeutics
  • Cellectis
  • Celyad
  • FOSUNKite
  • JW Therapeutics
  • Mustang Bio
  • Sorrento Therapeutics
  • Bristol-Myers Squibb
  • Gilead Sciences
  • Novartis
  • J & J

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Dynamics
  1. 2.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Trends
  2. 2.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Drivers
  3. 2.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Opportunities and Challenges
  4. 2.4 Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Restraints
3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Company
  1. 3.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Company Revenue Ranking in 2025
  2. 3.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue by Company (2021-2026)
  3. 3.3 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Company Ranking (2024-2026)
  4. 3.4 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Company Manufacturing Base and Headquarters
  5. 3.5 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Company Product Type and Application
  6. 3.6 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Chimeric Antigen Receptor (CAR) T-Cell Therapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Type
  1. 4.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Type Introduction
  2. 4.1.1 CD19-targeted
  3. 4.1.2 BCMA-targeted
  4. 4.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Type
  5. 4.2.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Type (2021-2032)
  7. 4.2.3 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type (2021-2032)
5 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Application
  1. 5.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Application Introduction
  2. 5.1.1 Lymphoma
  3. 5.1.2 Multiple Myeloma
  4. 5.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Application
  5. 5.2.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Application (2021-2032)
  7. 5.2.3 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application (2021-2032)
6 Chimeric Antigen Receptor (CAR) T-Cell Therapy Regional Value Analysis
  1. 6.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value (2021-2032)
  7. 6.3.2 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value (2021-2032)
  10. 6.4.2 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value (2021-2032)
  16. 6.6.2 South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Country, 2025 VS 2032
7 Chimeric Antigen Receptor (CAR) T-Cell Therapy Country-level Value Analysis
  1. 7.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Allogene Therapeutics
  2. 8.1.1 Allogene Therapeutics Company Information
  3. 8.1.2 Allogene Therapeutics Business Overview
  4. 8.1.3 Allogene Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Allogene Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  6. 8.1.5 Allogene Therapeutics Recent Developments
  7. 8.2 Autolus Therapeutics
  8. 8.2.1 Autolus Therapeutics Company Information
  9. 8.2.2 Autolus Therapeutics Business Overview
  10. 8.2.3 Autolus Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Autolus Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  12. 8.2.5 Autolus Therapeutics Recent Developments
  13. 8.3 Bluebird Bio
  14. 8.3.1 Bluebird Bio Company Information
  15. 8.3.2 Bluebird Bio Business Overview
  16. 8.3.3 Bluebird Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bluebird Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  18. 8.3.5 Bluebird Bio Recent Developments
  19. 8.4 CARsgen Therapeutics
  20. 8.4.1 CARsgen Therapeutics Company Information
  21. 8.4.2 CARsgen Therapeutics Business Overview
  22. 8.4.3 CARsgen Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 CARsgen Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  24. 8.4.5 CARsgen Therapeutics Recent Developments
  25. 8.5 Cellectis
  26. 8.5.1 Cellectis Company Information
  27. 8.5.2 Cellectis Business Overview
  28. 8.5.3 Cellectis Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Cellectis Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  30. 8.5.5 Cellectis Recent Developments
  31. 8.6 Celyad
  32. 8.6.1 Celyad Company Information
  33. 8.6.2 Celyad Business Overview
  34. 8.6.3 Celyad Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Celyad Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  36. 8.6.5 Celyad Recent Developments
  37. 8.7 FOSUNKite
  38. 8.7.1 FOSUNKite Company Information
  39. 8.7.2 FOSUNKite Business Overview
  40. 8.7.3 FOSUNKite Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue and Gross Margin (2021-2026)
  41. 8.7.4 FOSUNKite Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  42. 8.7.5 FOSUNKite Recent Developments
  43. 8.8 JW Therapeutics
  44. 8.8.1 JW Therapeutics Company Information
  45. 8.8.2 JW Therapeutics Business Overview
  46. 8.8.3 JW Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue and Gross Margin (2021-2026)
  47. 8.8.4 JW Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  48. 8.8.5 JW Therapeutics Recent Developments
  49. 8.9 Mustang Bio
  50. 8.9.1 Mustang Bio Company Information
  51. 8.9.2 Mustang Bio Business Overview
  52. 8.9.3 Mustang Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Mustang Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  54. 8.9.5 Mustang Bio Recent Developments
  55. 8.10 Sorrento Therapeutics
  56. 8.10.1 Sorrento Therapeutics Company Information
  57. 8.10.2 Sorrento Therapeutics Business Overview
  58. 8.10.3 Sorrento Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sorrento Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  60. 8.10.5 Sorrento Therapeutics Recent Developments
  61. 8.11 Bristol-Myers Squibb
  62. 8.11.1 Bristol-Myers Squibb Company Information
  63. 8.11.2 Bristol-Myers Squibb Business Overview
  64. 8.11.3 Bristol-Myers Squibb Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bristol-Myers Squibb Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  66. 8.11.5 Bristol-Myers Squibb Recent Developments
  67. 8.12 Gilead Sciences
  68. 8.12.1 Gilead Sciences Company Information
  69. 8.12.2 Gilead Sciences Business Overview
  70. 8.12.3 Gilead Sciences Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Gilead Sciences Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  72. 8.12.5 Gilead Sciences Recent Developments
  73. 8.13 Novartis
  74. 8.13.1 Novartis Company Information
  75. 8.13.2 Novartis Business Overview
  76. 8.13.3 Novartis Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Novartis Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  78. 8.13.5 Novartis Recent Developments
  79. 8.14 J & J
  80. 8.14.1 J & J Company Information
  81. 8.14.2 J & J Business Overview
  82. 8.14.3 J & J Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue and Gross Margin (2021-2026)
  83. 8.14.4 J & J Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  84. 8.14.5 J & J Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst